Effects of feeding condition on the myocardial and hepatic accumulation of radioiodine-labeled BMIPP in mice
- PDF / 773,268 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 192 Views
ORIGINAL ARTICLE
Effects of feeding condition on the myocardial and hepatic accumulation of radioiodine‑labeled BMIPP in mice Kazuaki Yamasaki1,2 · Songji Zhao1 · Mie Nishimura3 · Yoichi Shimizu4 · Nagara Tamaki1 · Hiroshi Takeda3 · Yuji Kuge1,4 Received: 4 June 2020 / Accepted: 23 September 2020 © The Japanese Society of Nuclear Medicine 2020
Abstract Objective 123I-15-(p-iodophenyl)-3(R,S)-methylpentadecanoic acid ([123I]BMIPP), a fatty acid analog, is widely used for the diagnosis of cardiac diseases. Feeding condition is one of the important factors in the myocardial fatty acid uptake, which may also affect myocardial accumulation of [123I]BMIPP and image quality of [123I]BMIPP scintigraphy. However, the relationship between the myocardial accumulation of [123I]BMIPP and the feeding condition is not entirely clear. Therefore, we determined the myocardial accumulation of [ 125I]BMIPP in mice at various metabolic statuses induced by fasting in comparison with the hepatic accumulation. Methods Fed or fasted (6-, 12-, and 24-h fasted) mice were intravenously injected with [125I]BMIPP (35.2–75.0 kBq, 4 nmol). Radioactivities in the heart and liver were measured at 1, 5, 10, 30, 60, and 120 min after the injection (n = 5–15/time point for each group), and then, the heart-to-liver (H/L) ratios were calculated. Results The myocardial accumulation level of [ 125I]BMIPP in the fed group was almost the same as that in the 6-h-fasted group at each time point, although it was decreased by 12- and 24-h fasting. The H/L ratios of [125I]BMIPP accumulation level were significantly decreased by fasting (1.92 ± 0.22, 1.45 ± 0.13, 1.12 ± 0.13, and 0.91 ± 0.15 at 10 min, and 3.30 ± 0.62, 2.09 ± 0.35, 1.79 ± 0.34, and 1.27 ± 0.06 at 30 min after the injection, respectively, for the fed group and the 6-, 12-, and 24-h-fasted groups; p ,@%0,33,9 6DFULILFHGDWDQGPLQDIWHUWKHLQMHFWLRQ DQGWLVVXHVDPSOLQJ Q –WLPHSRLQWIRUHDFKJURXS 0HDVXUHPHQWRIUDGLRDFWLYLW\ Q –WLPHSRLQWIRUHDFKJURXS
13
Annals of Nuclear Medicine
The remaining blood samples were used for biochemical examination [insulin, β-hydroxybutyrate (a most prevalent in serum and accounts for about 75% of all ketone bodies), non-esterified fatty acids (NEFAs), triglycerides (TGs), total cholesterol, free cholesterol, and high-density lipoprotein (HDL) cholesterol].
Measurement of blood parameters Before the [ 125I]BMIPP injection, the blood glucose levels of fed (fed ad libitum) or fasted (6-, 12-, and 24-h fasted) mice were measured by a glucometer (Accu-Chek; Roche Diagnostics, Tokyo, Japan) using the blood drawn from the tail vein without anesthesia. Insulin, β-hydroxybutyrate, NEFAs, TGs, total cholesterol, free cholesterol, and HDL cholesterol levels were measured using LBIS Mouse Insulin ELISA kit (Shibayagi, Gunma, Japan), β-hydroxybutyrate Assay Kit (BioVision, Milpitas, CA, USA) and NEFA C-test Wako, Triglyceride E-test Wako, Cholesterol E-test Wako, Free Cholesterol E-test Wako, and HDL-Cholesterol
Data Loading...
